AstraZeneca ended a Phase 3 volrustomig trial after failing to show benefit versus an existing standard in lung cancer, marking another retreat in its late-stage oncology pipeline. The decision followed an independent data monitoring committee’s review of interim results, according to the company. The stop further narrows the commercial and clinical opportunity for the bispecific strategy aimed at improving outcomes over immune checkpoint approaches. With multiple program pauses already hitting investor sentiment, volrustomig’s failure tightens timelines for AstraZeneca to replace lost optionality. Pipeline re-prioritization like this typically shifts resources toward earlier-stage candidates or alternate combinations, but volrustomig’s discontinuation will immediately affect trial staffing, regulatory planning, and development cost trajectories.